Landos Biopharma, Inc. financial data

Industry
Pharmaceutical Preparations
Location
1800 Kraft Drive, Suite 216, Blacksburg, VA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 730 % -20.3%
Debt-to-equity 15.9 % +29.5%
Return On Equity -73 % -8.91%
Return On Assets -63 % -5.51%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.12M shares -90%
Common Stock, Shares, Outstanding 3.12M shares -90%
Entity Public Float 5.6M USD -34.1%
Common Stock, Value, Issued 31K USD -90.1%
Weighted Average Number of Shares Outstanding, Basic 6.21M shares -4.27%
Weighted Average Number of Shares Outstanding, Diluted 6.21M shares -4.27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.8M USD -35.1%
General and Administrative Expense 13.7M USD -1.17%
Operating Income (Loss) -25.5M USD +20.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -24.8M USD +18.6%
Net Income (Loss) Attributable to Parent -24.8M USD +18.6%
Earnings Per Share, Basic -4 USD/shares +61.2%
Earnings Per Share, Diluted -4 USD/shares +61.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 29M USD -35.9%
Marketable Securities, Current 0 USD -100%
Assets, Current 29.9M USD -41.6%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 700K USD
Assets 29.9M USD -41.6%
Accounts Payable, Current 1.57M USD -31.9%
Accrued Liabilities, Current 5.18M USD +178%
Liabilities, Current 6.74M USD +62.1%
Liabilities 6.74M USD +62.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -164M USD -17.8%
Stockholders' Equity Attributable to Parent 23.2M USD -50.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 23.2M USD -50.8%
Liabilities and Equity 29.9M USD -41.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.5M USD -4.02%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 20M shares -90%
Common Stock, Shares, Issued 3.12M shares -90%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 8.6M USD +186%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 29.1M USD -35.8%
Deferred Tax Assets, Valuation Allowance 38.6M USD +14.2%
Depreciation 224K USD -55.7%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -24.9M USD +16.8%
Property, Plant and Equipment, Gross 166K USD -86.7%
Operating Lease, Liability, Current 27K USD
Deferred Tax Assets, Operating Loss Carryforwards 26.3M USD +14.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 317K USD -0.31%
Operating Lease, Payments 200K USD
Additional Paid in Capital 187M USD +0.69%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.01M USD -19.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%